OBE022

Research use only, not for human use.

OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM.

OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes; inhibits spontaneous, oxytocin- and PGF2α-induced human myometrial contractions alone and is more effective in combination with atosiban or nifedipine; reduces spontaneous contractions in near-term pregnant rat, OBE022 delayed RU486-induced parturition and exerted synergistic effects in combination with nifedipine; exhibits potent tocolytic effects on human tissues ex vivo and animal models in vivo without causing the adverse fetal side effects.Other Indication Phase 2 Clinical.

——

——

OBE 022 | OBE-022

GPCR/G Protein

Prostaglandin Receptor

Prostaglandin Receptor

Other Indications

Other Disease

2005486-32-6

636.194

C30H35ClFN3O5S2

>98% (HPLC)

——

N[C@@H](C(C)C)C(OCC[C@H](NC([C@@H]1SCCN1S(=O)(C2=CC=C(C3=CC=CC=C3)C=C2)=O)=O)C4=CC=C(F)C=C4)=O

(S)-2-Amino-3-methyl-butyric acid (S)-3-{[(S)-3-(biphenyl-4-sulfonyl)-thiazolidine-2-carbonyl]-amino}-3-(4-fluoro-phenyl)-propyl ester hydrochloride

(-20℃)

With Ice Pack

≥ 2 years